Free Trial
→ Prepare for the “Mar-a-Lago Accord” Money Shock (From Stansberry Research) (Ad)tc pixel Free RIGL Stock Alerts

Rigel Pharmaceuticals (RIGL) Financials

Rigel Pharmaceuticals logo
$34.72 -0.39 (-1.11%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$35.20 +0.48 (+1.38%)
As of 09/19/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Rigel Pharmaceuticals

Annual Income Statements for Rigel Pharmaceuticals

This table shows Rigel Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -59 -25 17
Consolidated Net Income / (Loss)		 -59 -25 17
Net Income / (Loss) Continuing Operations		 -59 -25 17
Total Pre-Tax Income 		-59 -25 18
Total Operating Income		 -56 -20 24
Total Gross Profit		 118 110 161
Total Revenue		 120 117 179
Operating Revenue		 120 117 179
Total Cost of Revenue		 1.75 7.11 19
Operating Cost of Revenue		 1.75 7.11 19
Total Operating Expenses		 174 130 136
Selling, General & Admin Expense		 112 106 113
Research & Development Expense		 60 25 23
Restructuring Charge		 1.32 0.00 0.00
Total Other Income / (Expense), net		 -3.02 -4.60 -5.83
Interest Expense		 3.71 6.87 7.92
Interest & Investment Income		 0.68 2.27 2.09
Income Tax Expense		 0.00 0.00 0.88
Basic Earnings per Share		 ($3.44) ($1.44) $0.99
Weighted Average Basic Shares Outstanding		 17.05M 17.40M 17.58M
Diluted Earnings per Share		 ($3.44) ($1.44) $0.99
Weighted Average Diluted Shares Outstanding		 17.05M 17.40M 17.69M
Weighted Average Basic & Diluted Shares Outstanding		 173.65M 175.38M 17.86M

Quarterly Income Statements for Rigel Pharmaceuticals

This table shows Rigel Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -19 1.40 -14 -6.60 -5.69 0.74 -8.25 -1.03 12 14
Consolidated Net Income / (Loss)		 -19 1.40 -14 -6.60 -5.69 0.74 -8.25 -1.03 12 14
Net Income / (Loss) Continuing Operations		 -19 1.40 -14 -6.60 -5.69 0.74 -8.25 -1.03 12 14
Total Pre-Tax Income 		-19 1.40 -14 -6.60 -5.69 0.74 -8.25 -1.03 12 15
Total Operating Income		 -18 2.08 -13 -5.27 -4.47 1.97 -6.97 0.45 14 17
Total Gross Profit		 22 51 25 26 27 32 28 34 47 52
Total Revenue		 22 51 26 27 28 36 30 37 55 58
Operating Revenue		 22 51 26 27 28 36 30 37 55 58
Total Cost of Revenue		 0.25 0.34 0.98 1.08 1.27 3.79 2.03 2.81 8.03 5.79
Operating Cost of Revenue		 0.25 0.34 0.98 1.08 1.27 3.79 2.03 2.81 8.03 5.79
Total Operating Expenses		 41 49 38 31 31 30 34 34 33 35
Selling, General & Admin Expense		 26 32 28 26 25 27 28 28 27 30
Research & Development Expense		 15 15 10 4.77 6.48 3.19 6.03 5.54 6.18 5.63
Total Other Income / (Expense), net		 -0.63 -0.68 -0.81 -1.33 -1.23 -1.23 -1.28 -1.48 -1.64 -1.43
Interest Expense		 0.83 1.11 1.20 1.86 1.90 1.91 1.87 2.03 2.06 1.96
Interest & Investment Income		 0.19 0.43 0.39 0.53 0.67 0.68 0.59 0.55 0.43 0.52
Basic Earnings per Share		 ($0.11) $0.08 ($0.08) ($0.38) ($0.33) $0.04 ($0.05) ($0.06) $0.71 $0.82
Weighted Average Basic Shares Outstanding		 172.84M 17.05M 173.57M 17.36M 17.44M 17.40M 175.20M 17.55M 17.60M 17.58M
Diluted Earnings per Share		 ($0.11) $0.08 ($0.08) ($0.38) ($0.33) $0.04 ($0.05) ($0.06) $0.70 $0.82
Weighted Average Diluted Shares Outstanding		 172.84M 17.05M 173.57M 17.36M 17.44M 17.40M 175.20M 17.55M 17.65M 17.69M
Basic & Diluted Earnings per Share		 - $0.08 - - - $0.04 - - - $0.82
Weighted Average Basic & Diluted Shares Outstanding		 172.84M 173.65M 173.67M 174.36M 174.37M 175.38M 175.41M 17.59M 17.62M 17.86M

Annual Cash Flow Statements for Rigel Pharmaceuticals

This table details how cash moves in and out of Rigel Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 5.57 8.33 24
Net Cash From Operating Activities		 -74 -5.74 31
Net Cash From Continuing Operating Activities		 -74 -5.74 31
Net Income / (Loss) Continuing Operations		 -59 -25 17
Consolidated Net Income / (Loss)		 -59 -25 17
Depreciation Expense		 1.00 1.24 2.23
Amortization Expense		 -0.06 -0.48 -0.71
Non-Cash Adjustments To Reconcile Net Income		 13 9.07 12
Changes in Operating Assets and Liabilities, net		 -29 9.52 0.15
Net Cash From Investing Activities		 73 -4.30 4.13
Net Cash From Continuing Investing Activities		 73 -4.30 4.13
Purchase of Property, Plant & Equipment		 - 0.00 -0.04
Acquisitions		 0.00 -15 -0.36
Purchase of Investments		 -29 -31 -35
Sale of Property, Plant & Equipment		 0.89 0.26 0.10
Sale and/or Maturity of Investments		 101 42 40
Net Cash From Financing Activities		 6.55 18 -12
Net Cash From Continuing Financing Activities		 6.55 18 -12
Issuance of Debt		 20 20 0.00
Issuance of Common Equity		 2.12 1.05 1.96
Other Financing Activities, net		 -15 -2.63 -14
Cash Interest Paid		 2.50 5.85 7.04
Cash Income Taxes Paid		 0.00 0.00 0.33

Quarterly Cash Flow Statements for Rigel Pharmaceuticals

This table details how cash moves in and out of Rigel Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 2.67 -5.41 16 8.53 -3.40 -13 -7.21 10 16 5.05
Net Cash From Operating Activities		 -13 -22 -4.07 5.93 -1.36 -6.24 -5.01 0.30 22 15
Net Cash From Continuing Operating Activities		 -13 -22 -4.07 5.93 -1.36 -6.24 -5.01 0.30 22 15
Net Income / (Loss) Continuing Operations		 -19 1.40 -14 -6.60 -5.69 0.74 -8.25 -1.03 12 14
Consolidated Net Income / (Loss)		 -19 1.40 -14 -6.60 -5.69 0.74 -8.25 -1.03 12 14
Depreciation Expense		 0.24 0.28 0.36 0.30 0.29 0.29 0.40 0.61 0.61 0.60
Amortization Expense		 0.01 -0.18 -0.07 -0.05 -0.11 -0.26 -0.21 -0.16 -0.07 -0.28
Non-Cash Adjustments To Reconcile Net Income		 2.50 4.41 3.11 2.22 1.92 1.82 5.13 2.53 2.62 2.03
Changes in Operating Assets and Liabilities, net		 2.99 -28 6.07 10 2.23 -8.83 -2.10 -1.65 6.10 -2.20
Net Cash From Investing Activities		 10 19 0.78 2.97 -1.17 -6.87 0.31 11 3.80 -11
Net Cash From Continuing Investing Activities		 10 19 0.78 2.97 -1.17 -6.87 0.31 11 3.80 -11
Purchase of Property, Plant & Equipment		 -0.19 - - - - - - - - -0.03
Purchase of Investments		 -19 -2.85 0.00 -8.78 -9.44 -13 -7.80 -7.55 -2.21 -18
Sale of Property, Plant & Equipment		 0.28 0.35 0.13 - 0.02 0.11 0.00 - 0.03 0.07
Sale and/or Maturity of Investments		 29 21 16 12 8.25 6.00 8.25 19 6.00 6.75
Net Cash From Financing Activities		 5.51 -2.10 19 -0.37 -0.87 0.49 -2.51 -0.75 -9.84 1.47
Net Cash From Continuing Financing Activities		 5.51 -2.10 19 -0.37 -0.87 0.49 -2.51 -0.75 -9.84 1.47
Issuance of Common Equity		 - 0.59 0.00 0.55 0.01 0.49 0.09 0.25 0.16 1.47
Cash Interest Paid		 0.60 0.95 1.01 1.47 1.68 1.68 1.68 1.77 1.84 1.75

Annual Balance Sheets for Rigel Pharmaceuticals

This table presents Rigel Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 134 117 164
Total Current Assets		 116 99 135
Cash & Equivalents		 24 33 57
Short-Term Investments		 34 24 21
Accounts Receivable		 40 31 42
Inventories, net		 9.12 5.52 6.00
Prepaid Expenses		 8.26 6.26 10
Plant, Property, & Equipment, net		 0.86 0.17 0.09
Total Noncurrent Assets		 18 18 29
Goodwill		 15 14 27
Other Noncurrent Operating Assets		 2.57 3.92 1.68
Total Liabilities & Shareholders' Equity		 134 117 164
Total Liabilities		 148 146 161
Total Current Liabilities		 65 53 63
Short-Term Debt		 0.00 7.23 7.27
Accounts Payable		 23 7.14 3.34
Accrued Expenses		 14 8.85 14
Current Deferred Revenue		 1.37 1.36 1.36
Current Employee Benefit Liabilities		 8.87 8.68 10
Other Current Liabilities		 18 20 27
Total Noncurrent Liabilities		 83 93 97
Long-Term Debt		 39 52 52
Capital Lease Obligations		 0.97 0.29 0.00
Other Noncurrent Operating Liabilities		 42 40 45
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -14 -29 3.29
Total Preferred & Common Equity		 -14 -29 3.29
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -14 -29 3.29
Common Stock		 1,369 1,379 1,393
Retained Earnings		 -1,382 -1,408 -1,390
Accumulated Other Comprehensive Income / (Loss)		 -0.15 0.01 0.01

Quarterly Balance Sheets for Rigel Pharmaceuticals

This table presents Rigel Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 116 124 117 115 127 128 139
Total Current Assets		 110 107 101 95 92 95 106
Cash & Equivalents		 30 40 49 45 26 36 52
Short-Term Investments		 52 18 16 17 24 13 9.42
Accounts Receivable		 16 29 21 24 28 29 31
Inventories, net		 7.12 11 11 6.11 6.58 8.06 4.78
Prepaid Expenses		 6.16 7.87 4.97 3.02 8.85 8.66 9.99
Plant, Property, & Equipment, net		 1.69 0.29 0.22 0.19 0.14 0.12 0.10
Total Noncurrent Assets		 3.48 16 16 20 34 34 33
Goodwill		 - 15 14 14 29 28 28
Other Noncurrent Operating Assets		 3.48 1.67 1.54 5.96 5.03 5.30 5.17
Total Liabilities & Shareholders' Equity		 116 124 117 115 127 128 139
Total Liabilities		 135 148 145 147 158 158 154
Total Current Liabilities		 47 46 44 48 73 59 54
Short-Term Debt		 - - - - 15 0.00 0.00
Accounts Payable		 2.72 6.30 5.24 8.00 9.28 6.13 3.82
Accrued Expenses		 25 12 11 11 9.56 11 14
Current Deferred Revenue		 1.37 1.37 1.36 1.36 1.36 1.36 1.36
Current Employee Benefit Liabilities		 8.77 5.66 6.74 8.09 5.25 6.37 7.92
Other Current Liabilities		 9.23 20 20 20 33 34 28
Total Noncurrent Liabilities		 88 102 101 99 85 100 100
Long-Term Debt		 39 59 60 60 45 60 60
Capital Lease Obligations		 0.00 0.80 0.63 0.47 0.10 0.00 0.00
Other Noncurrent Operating Liabilities		 49 42 41 39 40 40 40
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -20 -24 -28 -32 -32 -30 -15
Total Preferred & Common Equity		 -20 -24 -28 -32 -32 -30 -15
Total Common Equity		 -20 -24 -28 -32 -32 -30 -15
Common Stock		 1,364 1,372 1,375 1,376 1,384 1,387 1,390
Retained Earnings		 -1,384 -1,396 -1,403 -1,408 -1,416 -1,417 -1,404
Accumulated Other Comprehensive Income / (Loss)		 -0.29 -0.03 -0.03 -0.02 -0.01 -0.01 0.01

Annual Metrics And Ratios for Rigel Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rigel Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 -19.43% -2.79% 53.38%
EBITDA Growth		 -394.39% 63.87% 230.30%
EBIT Growth		 -344.54% 63.11% 218.06%
NOPAT Growth		 -344.54% 63.11% 260.57%
Net Income Growth		 -226.97% 57.16% 169.69%
EPS Growth		 -226.97% 57.16% 168.75%
Operating Cash Flow Growth		 -1,354.81% 92.21% 647.99%
Free Cash Flow Firm Growth		 -212.53% 75.36% 158.31%
Invested Capital Growth		 57.52% 18.19% 44.13%
Revenue Q/Q Growth		 34.54% -11.70% 13.85%
EBITDA Q/Q Growth		 29.71% -0.95% 139.68%
EBIT Q/Q Growth		 29.73% -0.55% 154.57%
NOPAT Q/Q Growth		 29.73% -0.55% 142.36%
Net Income Q/Q Growth		 29.10% -2.72% 350.53%
EPS Q/Q Growth		 29.10% -2.72% 350.00%
Operating Cash Flow Q/Q Growth		 -3.98% 73.18% 193.35%
Free Cash Flow Firm Q/Q Growth		 -21.65% 52.49% 236.47%
Invested Capital Q/Q Growth		 49.36% 24.57% 10.23%
Profitability Metrics		 - - -
Gross Margin		 98.55% 93.92% 89.60%
EBITDA Margin		 -45.42% -16.88% 14.34%
Operating Margin		 -46.20% -17.53% 13.49%
EBIT Margin		 -46.20% -17.53% 13.49%
Profit (Net Income) Margin		 -48.71% -21.47% 9.75%
Tax Burden Percent		 100.00% 100.00% 95.20%
Interest Burden Percent		 105.44% 122.45% 75.92%
Effective Tax Rate		 0.00% 0.00% 4.80%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -699.05% 118.75% -137.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -36.84% -16.29% 17.21%
Return on Assets (ROA)		 -38.84% -19.95% 12.44%
Return on Common Equity (ROCE)		 -699.05% 118.75% -137.92%
Return on Equity Simple (ROE_SIMPLE)		 430.18% 87.60% 531.78%
Net Operating Profit after Tax (NOPAT)		 -39 -14 23
NOPAT Margin		 -32.34% -12.27% 12.85%
Net Nonoperating Expense Percent (NNEP)		 -32.25% -144.92% -75.53%
Return On Investment Capital (ROIC_SIMPLE)		 -145.07% -45.91% 36.58%
Cost of Revenue to Revenue		 1.45% 6.08% 10.40%
SG&A Expenses to Revenue		 93.52% 90.47% 63.06%
R&D to Revenue		 50.13% 20.98% 13.04%
Operating Expenses to Revenue		 144.74% 111.45% 76.10%
Earnings before Interest and Taxes (EBIT)		 -56 -20 24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -55 -20 26
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 90.11
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.16 2.16 1.65
Price to Earnings (P/E)		 0.00 0.00 16.95
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 5.90%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.01 2.19 1.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 10.84
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 11.52
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 12.10
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 8.85
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 23.83
Leverage & Solvency		 - - -
Debt to Equity		 -2.97 -2.09 18.15
Long-Term Debt to Equity		 -2.97 -1.84 15.94
Financial Leverage		 -7.28 0.35 0.58
Leverage Ratio		 18.00 -5.95 -11.09
Compound Leverage Factor		 18.98 -7.29 -8.42
Debt to Total Capital		 150.80% 191.68% 94.78%
Short-Term Debt to Total Capital		 0.00% 23.14% 11.55%
Long-Term Debt to Total Capital		 150.80% 168.54% 83.23%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -50.80% -91.68% 5.22%
Debt to EBITDA		 -0.74 -3.04 2.32
Net Debt to EBITDA		 0.33 -0.15 -0.69
Long-Term Debt to EBITDA		 -0.74 -2.67 2.04
Debt to NOPAT		 -1.04 -4.18 2.59
Net Debt to NOPAT		 0.46 -0.21 -0.77
Long-Term Debt to NOPAT		 -1.04 -3.67 2.28
Altman Z-Score		 -13.38 -14.88 -8.66
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 1.78 1.86 2.13
Quick Ratio		 1.51 1.64 1.88
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -81 -20 12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -21.96 -2.92 1.48
Operating Cash Flow to Interest Expense		 -19.90 -0.84 3.97
Operating Cash Flow Less CapEx to Interest Expense		 -19.66 -0.80 3.98
Efficiency Ratios		 - - -
Asset Turnover		 0.80 0.93 1.28
Accounts Receivable Turnover		 4.31 3.30 4.97
Inventory Turnover		 0.22 0.97 3.24
Fixed Asset Turnover		 79.08 228.73 1,395.16
Accounts Payable Turnover		 0.13 0.48 3.56
Days Sales Outstanding (DSO)		 84.68 110.66 73.46
Days Inventory Outstanding (DIO)		 1,641.77 375.78 112.79
Days Payable Outstanding (DPO)		 2,744.60 761.06 102.58
Cash Conversion Cycle (CCC)		 -1,018.15 -274.62 83.67
Capital & Investment Metrics		 - - -
Invested Capital		 -31 -26 -14
Invested Capital Turnover		 -2.28 -4.09 -8.95
Increase / (Decrease) in Invested Capital		 43 5.71 11
Enterprise Value (EV)		 241 256 279
Market Capitalization		 259 253 296
Book Value per Share		 ($0.08) ($0.16) $0.19
Tangible Book Value per Share		 ($0.17) ($0.24) ($1.35)
Total Capital		 27 31 63
Total Debt		 40 60 60
Total Long-Term Debt		 40 53 52
Net Debt		 -18 2.95 -18
Capital Expenditures (CapEx)		 -0.89 -0.26 -0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.51 -3.71 1.76
Debt-free Net Working Capital (DFNWC)		 51 53 79
Net Working Capital (NWC)		 51 46 72
Net Nonoperating Expense (NNE)		 20 11 5.55
Net Nonoperating Obligations (NNO)		 -18 2.95 -18
Total Depreciation and Amortization (D&A)		 0.94 0.76 1.52
Debt-free, Cash-free Net Working Capital to Revenue		 -6.25% -3.17% 0.98%
Debt-free Net Working Capital to Revenue		 42.16% 45.54% 44.11%
Net Working Capital to Revenue		 42.16% 39.36% 40.05%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.40) ($1.40) $0.99
Adjusted Weighted Average Basic Shares Outstanding		 17.24M 17.40M 17.58M
Adjusted Diluted Earnings per Share		 ($3.40) ($1.40) $0.99
Adjusted Weighted Average Diluted Shares Outstanding		 17.24M 17.40M 17.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 17.37M 17.54M 17.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -14 23
Normalized NOPAT Margin		 -31.57% -12.27% 12.85%
Pre Tax Income Margin		 -48.71% -21.47% 10.24%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -14.99 -2.98 3.06
NOPAT to Interest Expense		 -10.49 -2.09 2.91
EBIT Less CapEx to Interest Expense		 -14.74 -2.94 3.06
NOPAT Less CapEx to Interest Expense		 -10.25 -2.05 2.92
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Rigel Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rigel Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 4.02% 151.25% 55.78% -9.84% 25.54% -30.20% 13.29% 37.03% 96.58% 60.92%
EBITDA Growth		 6.65% 110.45% 52.16% 60.34% 76.43% -8.47% 45.55% 117.96% 441.23% 749.57%
EBIT Growth		 6.99% 109.71% 51.54% 59.38% 75.74% -5.44% 45.26% 108.49% 414.80% 747.15%
NOPAT Growth		 6.99% 113.87% 51.54% 59.38% 75.74% -5.44% 45.26% 108.49% 549.72% 747.15%
Net Income Growth		 9.14% 106.19% 50.68% 51.08% 70.10% -47.39% 39.07% 84.39% 318.22% 1,845.86%
EPS Growth		 8.33% 106.19% 50.00% 51.08% 70.10% -47.39% 37.50% 84.21% 312.12% 1,950.00%
Operating Cash Flow Growth		 -29.17% -14.79% 84.11% 145.93% 89.78% 71.52% -23.05% -94.91% 1,695.22% 332.42%
Free Cash Flow Firm Growth		 -142.38% -161.19% -151.35% -199.75% -27.02% 90.74% 89.36% 63.30% 87.08% 241.96%
Invested Capital Growth		 15.74% 57.52% 68.07% 48.78% 45.07% 18.19% 5.31% 40.12% 53.06% 44.13%
Revenue Q/Q Growth		 -24.85% 128.82% -49.16% 3.13% 4.64% 27.22% -17.48% 24.74% 50.12% 4.14%
EBITDA Q/Q Growth		 -43.52% 112.03% -669.41% 59.66% 14.73% 146.73% -438.72% 113.31% 1,520.20% 16.34%
EBIT Q/Q Growth		 -41.94% 111.30% -712.07% 58.61% 15.23% 144.03% -454.32% 106.42% 3,044.52% 18.49%
NOPAT Q/Q Growth		 -41.94% 116.14% -528.45% 58.61% 15.23% 162.90% -348.03% 106.42% 4,392.17% 18.49%
Net Income Q/Q Growth		 -41.10% 107.36% -1,066.17% 51.24% 13.76% 112.95% -1,219.00% 87.51% 1,305.92% 15.46%
EPS Q/Q Growth		 -37.50% 107.36% -900.00% 51.24% 13.76% 112.95% 0.00% -20.00% 1,266.67% 17.14%
Operating Cash Flow Q/Q Growth		 -3.02% -64.72% 81.40% 245.56% -122.92% -359.16% 19.66% 106.02% 7,078.48% -33.10%
Free Cash Flow Firm Q/Q Growth		 -113.01% -65.31% -41.32% 39.76% 9.74% 87.94% -62.26% -107.84% 68.21% 232.42%
Invested Capital Q/Q Growth		 1.59% 49.36% 27.93% -42.58% -5.55% 24.57% 16.58% 9.83% 17.26% 10.23%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 98.88% 99.33% 96.25% 96.00% 95.49% 89.41% 93.14% 92.38% 85.49% 89.95%
EBITDA Margin		 -81.01% 4.26% -47.70% -18.66% -15.21% 5.59% -22.93% 2.45% 26.39% 29.49%
Operating Margin		 -82.12% 4.05% -48.81% -19.59% -15.87% 5.49% -23.59% 1.21% 25.41% 28.92%
EBIT Margin		 -82.12% 4.05% -48.81% -19.59% -15.87% 5.49% -23.59% 1.21% 25.41% 28.92%
Profit (Net Income) Margin		 -84.95% 2.73% -51.92% -24.55% -20.23% 2.06% -27.92% -2.80% 22.46% 24.90%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 94.21%
Interest Burden Percent		 103.45% 67.39% 106.37% 125.31% 127.48% 37.49% 118.39% -230.43% 88.37% 91.40%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -553.79% -699.05% 511.64% 237.62% 94.55% 118.75% 70.81% 49.05% -16.70% -137.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -48.58% 3.23% -46.39% -20.25% -18.19% 5.11% -22.70% 1.29% 31.42% 36.87%
Return on Assets (ROA)		 -50.26% 2.18% -49.35% -25.37% -23.19% 1.91% -26.87% -2.97% 27.77% 31.75%
Return on Common Equity (ROCE)		 -553.79% -699.05% 511.64% 237.62% 94.55% 118.75% 70.81% 49.05% -16.70% -137.92%
Return on Equity Simple (ROE_SIMPLE)		 416.53% 0.00% 184.13% 134.35% 76.73% 0.00% 62.52% 47.58% -26.52% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 2.08 -8.91 -3.69 -3.13 1.97 -4.88 0.31 14 17
NOPAT Margin		 -57.48% 4.05% -34.17% -13.71% -11.11% 5.49% -16.51% 0.85% 25.41% 28.92%
Net Nonoperating Expense Percent (NNEP)		 -7.44% -1.11% -12.17% -9.18% -11.56% -16.57% 56.82% 41.74% -91.39% -31.51%
Return On Investment Capital (ROIC_SIMPLE)		 - 7.76% - - - 6.29% - - - 26.45%
Cost of Revenue to Revenue		 1.12% 0.67% 3.75% 4.00% 4.51% 10.59% 6.86% 7.62% 14.51% 10.05%
SG&A Expenses to Revenue		 115.56% 62.74% 106.36% 97.84% 88.35% 75.02% 96.33% 76.13% 48.90% 51.25%
R&D to Revenue		 65.44% 29.96% 38.70% 17.75% 23.01% 8.90% 20.40% 15.04% 11.18% 9.78%
Operating Expenses to Revenue		 181.00% 95.28% 145.06% 115.59% 111.36% 83.92% 116.73% 91.17% 60.07% 61.03%
Earnings before Interest and Taxes (EBIT)		 -18 2.08 -13 -5.27 -4.47 1.97 -6.97 0.45 14 17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 2.18 -12 -5.02 -4.28 2.00 -6.77 0.90 15 17
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 90.11
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.28 2.16 1.77 1.77 1.42 2.16 2.16 1.11 1.81 1.65
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 73.35 16.95
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.36% 5.90%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1.81 2.01 1.78 1.74 1.41 2.19 2.24 1.19 1.80 1.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 26.41 10.84
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.82 11.52
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.82 12.10
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 26.41 8.85
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.83
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -1.99 -2.97 -2.49 -2.14 -1.89 -2.09 -1.89 -2.00 -4.08 18.15
Long-Term Debt to Equity		 -1.99 -2.97 -2.49 -2.14 -1.89 -1.84 -1.42 -2.00 -4.08 15.94
Financial Leverage		 -5.54 -7.28 4.36 2.00 0.86 0.35 -0.21 -0.11 0.08 0.58
Leverage Ratio		 10.13 18.00 -15.62 -7.71 -4.47 -5.95 -4.47 -4.23 -5.48 -11.09
Compound Leverage Factor		 10.48 12.13 -16.61 -9.66 -5.70 -2.23 -5.29 9.75 -4.84 -10.14
Debt to Total Capital		 201.02% 150.80% 167.33% 187.62% 212.52% 191.68% 212.63% 200.46% 132.43% 94.78%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 23.14% 52.56% 0.00% 0.00% 11.55%
Long-Term Debt to Total Capital		 201.02% 150.80% 167.33% 187.62% 212.52% 168.54% 160.07% 200.46% 132.43% 83.23%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -101.02% -50.80% -67.33% -87.62% -112.52% -91.68% -112.63% -100.46% -32.43% 5.22%
Debt to EBITDA		 -0.51 -0.74 -1.47 -1.80 -3.08 -3.04 -4.25 -7.33 5.57 2.32
Net Debt to EBITDA		 0.54 0.33 -0.04 0.12 0.11 -0.15 -0.73 -1.30 -0.13 -0.69
Long-Term Debt to EBITDA		 -0.51 -0.74 -1.47 -1.80 -3.08 -2.67 -3.20 -7.33 5.57 2.04
Debt to NOPAT		 -0.71 -1.04 -2.05 -2.51 -4.22 -4.18 -5.80 -9.46 6.29 2.59
Net Debt to NOPAT		 0.76 0.46 -0.06 0.17 0.16 -0.21 -0.99 -1.68 -0.14 -0.77
Long-Term Debt to NOPAT		 -0.71 -1.04 -2.05 -2.51 -4.22 -3.67 -4.36 -9.46 6.29 2.28
Altman Z-Score		 -14.95 -11.96 -13.58 -14.33 -14.82 -14.25 -13.73 -13.54 -11.08 -8.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.34 1.78 2.35 2.29 1.97 1.86 1.26 1.62 1.96 2.13
Quick Ratio		 2.06 1.51 1.93 1.93 1.78 1.64 1.05 1.33 1.69 1.88
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -40 -57 -34 -31 -3.75 -6.08 -13 -4.02 5.32
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -29.62 -36.53 -47.47 -18.49 -16.36 -1.96 -3.24 -6.23 -1.95 2.72
Operating Cash Flow to Interest Expense		 -16.10 -19.79 -3.38 3.18 -0.72 -3.27 -2.68 0.15 10.52 7.42
Operating Cash Flow Less CapEx to Interest Expense		 -15.99 -19.48 -3.28 3.18 -0.70 -3.21 -2.68 0.15 10.54 7.44
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.59 0.80 0.95 1.03 1.15 0.93 0.96 1.06 1.24 1.28
Accounts Receivable Turnover		 5.86 4.31 5.81 6.66 6.78 3.30 4.23 5.24 5.82 4.97
Inventory Turnover		 0.27 0.22 0.29 0.31 0.55 0.97 0.92 1.05 3.06 3.24
Fixed Asset Turnover		 41.10 79.08 106.47 123.74 140.52 228.73 554.59 789.70 1,089.79 1,395.16
Accounts Payable Turnover		 0.65 0.13 0.48 0.72 0.68 0.48 1.05 1.74 2.82 3.56
Days Sales Outstanding (DSO)		 62.31 84.68 62.82 54.78 53.87 110.66 86.25 69.64 62.72 73.46
Days Inventory Outstanding (DIO)		 1,363.55 1,641.77 1,249.90 1,173.41 659.23 375.78 394.98 347.67 119.45 112.79
Days Payable Outstanding (DPO)		 565.13 2,744.60 764.26 510.43 534.24 761.06 348.33 209.81 129.51 102.58
Cash Conversion Cycle (CCC)		 860.73 -1,018.15 548.46 717.76 178.86 -274.62 132.90 207.50 52.66 83.67
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -62 -31 -23 -32 -34 -26 -21 -19 -16 -14
Invested Capital Turnover		 -1.32 -2.28 -2.77 -2.66 -2.76 -4.09 -5.46 -5.05 -6.29 -8.95
Increase / (Decrease) in Invested Capital		 12 43 48 31 28 5.71 1.20 13 18 11
Enterprise Value (EV)		 162 241 231 220 186 256 270 155 283 279
Market Capitalization		 204 259 229 224 188 253 260 144 285 296
Book Value per Share		 ($0.11) ($0.08) ($0.14) ($0.16) ($0.18) ($0.16) ($0.18) ($0.17) ($0.83) $0.19
Tangible Book Value per Share		 ($0.11) ($0.17) ($0.22) ($0.24) ($0.26) ($0.24) ($0.35) ($0.33) ($2.41) ($1.35)
Total Capital		 20 27 36 32 28 31 28 30 45 63
Total Debt		 39 40 60 60 60 60 60 60 60 60
Total Long-Term Debt		 39 40 60 60 60 53 45 60 60 52
Net Debt		 -42 -18 1.62 -4.16 -2.23 2.95 10 11 -1.35 -18
Capital Expenditures (CapEx)		 -0.09 -0.35 -0.13 0.00 -0.02 -0.11 0.00 0.00 -0.03 -0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -7.51 2.79 -7.46 -16 -3.71 -15 -13 -8.96 1.76
Debt-free Net Working Capital (DFNWC)		 63 51 61 57 47 53 34 36 52 79
Net Working Capital (NWC)		 63 51 61 57 47 46 19 36 52 72
Net Nonoperating Expense (NNE)		 6.15 0.68 4.63 2.91 2.57 1.23 3.37 1.34 1.64 2.31
Net Nonoperating Obligations (NNO)		 -42 -18 1.62 -4.16 -2.23 2.95 10 11 -1.35 -18
Total Depreciation and Amortization (D&A)		 0.25 0.11 0.29 0.25 0.19 0.03 0.20 0.45 0.54 0.33
Debt-free, Cash-free Net Working Capital to Revenue		 -20.66% -6.25% 2.15% -5.89% -11.79% -3.17% -12.86% -10.00% -5.69% 0.98%
Debt-free Net Working Capital to Revenue		 70.69% 42.16% 47.43% 44.93% 35.32% 45.54% 28.31% 27.69% 33.12% 44.11%
Net Working Capital to Revenue		 70.69% 42.16% 47.43% 44.93% 35.32% 39.36% 16.03% 27.69% 33.12% 40.05%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.10) $0.80 ($0.80) ($0.40) ($0.30) $0.40 ($0.50) ($0.06) $0.71 $0.82
Adjusted Weighted Average Basic Shares Outstanding		 17.28M 1.70M 17.36M 17.37M 17.44M 1.74M 17.52M 17.55M 17.60M 17.58M
Adjusted Diluted Earnings per Share		 ($1.10) $0.80 ($0.80) ($0.40) ($0.30) $0.40 ($0.50) ($0.06) $0.70 $0.82
Adjusted Weighted Average Diluted Shares Outstanding		 17.28M 1.70M 17.36M 17.37M 17.44M 1.74M 17.52M 17.55M 17.65M 17.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.80 $0.00 $0.00 $0.00 $0.40 $0.00 $0.00 $0.00 $0.82
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 17.28M 17.37M 17.37M 17.44M 17.44M 17.54M 17.54M 17.59M 17.62M 17.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 1.46 -8.91 -3.69 -3.13 1.38 -4.88 0.31 9.84 12
Normalized NOPAT Margin		 -57.48% 2.84% -34.17% -13.71% -11.11% 3.85% -16.51% 0.85% 17.79% 20.24%
Pre Tax Income Margin		 -84.95% 2.73% -51.92% -24.55% -20.23% 2.06% -27.92% -2.80% 22.46% 26.43%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -22.28 1.88 -10.57 -2.83 -2.35 1.03 -3.72 0.22 6.82 8.52
NOPAT to Interest Expense		 -15.60 1.88 -7.40 -1.98 -1.65 1.03 -2.60 0.15 6.82 8.52
EBIT Less CapEx to Interest Expense		 -22.17 2.19 -10.46 -2.83 -2.34 1.09 -3.72 0.22 6.84 8.54
NOPAT Less CapEx to Interest Expense		 -15.49 2.19 -7.29 -1.98 -1.63 1.09 -2.60 0.15 6.84 8.54
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rigel Pharmaceuticals (NASDAQ:RIGL) Financial Summary and Analysis (2022 - 2024)

Rigel Pharmaceuticals has demonstrated notable changes across its financials over the last several quarters and years, showing trends in revenue growth, profitability, cash flows, and balance sheet strength. Below is an analysis focusing on the key financial metrics and their trajectory.

  • Operating revenue has grown significantly from approximately $26.1 million in Q1 2023 to $57.6 million in Q4 2024, more than doubling within less than two years, showing strong top-line growth momentum.
  • Net income turned positive and improved markedly from a loss of $13.5 million in Q1 2023 to a net income of $14.3 million in Q4 2024, indicating improving profitability and operational leverage.
  • Gross profit margin shows improvement with total gross profit rising from about $25 million in early 2023 to over $51.8 million in Q4 2024, highlighting better cost control or higher-margin products.
  • Operating income moved from significant losses in early 2023 to a positive $16.7 million by Q4 2024, signalling effective expense management and core business improvement.
  • Net cash from operating activities surged from negative or marginal levels in early 2023 to a positive $14.5 million in Q4 2024, reinforcing operational cash flow strength.
  • Issuance of common equity has provided incremental cash inflows in recent quarters supporting liquidity and financial flexibility.
  • Research & Development (R&D) expenses fluctuated but remain significant, indicating sustained investment in pipeline and innovation, typical for a biopharma company.
  • Interest expense remains stable around $1.2M to $2.1M quarterly, reflecting existing debt levels; interest income partly offsets this.
  • Balance sheet liabilities are high with total liabilities exceeding total assets, resulting in negative shareholders’ equity in recent periods, a typical scenario in biotech firms focused on growth and R&D.
  • The company maintains a significant goodwill balance reflecting past acquisitions or intangibles, which may impact future impairment risk.
  • Despite improving profits, Rigel's long-term debt stays substantial (approximately $44.9M in Q1 2024 rising to nearly $60M by Q3 2024), potentially increasing financial risk and interest burden.
  • Negative shareholders’ equity persists through the periods analyzed, indicating accumulated losses historically, which might concern long-term sustainability absent continued growth.
  • Total operating expenses remain high relative to revenue earlier in the period, with SG&A and R&D comprising major costs; any increase without commensurate revenue growth could pressure margins.
  • The company experienced periods of negative operating and net income in 2022 and early 2023, indicating volatile profitability before recent improvements.
  • Large swings in cash from investments—mainly large purchases and sales of investments—cause cash flow volatility, which could affect financial planning.

Summary: Rigel Pharmaceuticals is showing a robust recovery and expansion trajectory in 2024, with substantial revenue growth and a return to profitability and positive cash flow generation. However, its high leverage, negative equity base, and ongoing investment in R&D pose risks. Retail investors should watch for sustained profitability, debt management, and R&D pipeline success to support future valuation and growth.

09/20/25 02:13 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

When does Rigel Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Rigel Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Rigel Pharmaceuticals' net income changed over the last 2 years?

Rigel Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $17.49 million in 2024, falling from -$58.57 million in 2022. The previous period was -$25.09 million in 2023. Find out what analysts predict for Rigel Pharmaceuticals in the coming months.

What is Rigel Pharmaceuticals' operating income?
Rigel Pharmaceuticals' total operating income in 2024 was $24.19 million, based on the following breakdown:
  • Total Gross Profit: $160.63 million
  • Total Operating Expenses: $136.44 million
How has Rigel Pharmaceuticals' revenue changed over the last 2 years?

Over the last 2 years, Rigel Pharmaceuticals' total revenue changed from $120.24 million in 2022 to $179.28 million in 2024, a change of 49.1%.

How much debt does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals' total liabilities were at $160.69 million at the end of 2024, a 10.2% increase from 2023, and a 8.7% increase since 2022.

How much cash does Rigel Pharmaceuticals have?

In the past 2 years, Rigel Pharmaceuticals' cash and equivalents has ranged from $24.46 million in 2022 to $56.75 million in 2024, and is currently $56.75 million as of their latest financial filing in 2024.

How has Rigel Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Rigel Pharmaceuticals' book value per share changed from -0.08 in 2022 to 0.19 in 2024, a change of -336.9%.


Related Companies

This page (NASDAQ:RIGL) was last updated on 9/20/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...
Crypto 101 Media | Sponsoredtc pixel
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...
Porter & Company | Sponsoredtc pixel
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...
Brownstone Research | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
College grad makes $64,000 a month
A Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...
Stansberry Research | Sponsoredtc pixel
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...
Weiss Ratings | Sponsoredtc pixel